Association between RA disease characteristics and sarcopenia
EWGSOP2 | FNIH | |||||||
Crude ORs (95% CI) | P value | Adjusted* ORs (95% CI) | P value | Crude ORs (95% CI) | P value | Adjusted* ORs (95% CI) | P value | |
Sex | ||||||||
Male | ref. | – | – | ref. | – | – | ||
Female | 0.56 (0.17 to 1.89) | 0.35 | – | – | 0.42 (0.10 to 1.79) | 0.34 | – | – |
Age (years) | 1.03 (0.97 to 1.08) | 0.36 | – | – | 1.10 (1.00 to 1.14) | 0.12 | – | – |
Height (cm) | 1.05 (0.99 to 1.13) | 0.13 | 1.08 (0.98 to 1.19) | 0.14 | 0.87 (0.78 to 0.96) | 0.006 | 0.75 (0.64 to 0.88) | 0.0003 |
Weight (kg) | 0.95 (0.90 to 0.99) | 0.03 | 0.92 (0.86 to 0.97) | 0.006 | 1.01 (0.96 to 1.01) | 0.61 | 1.01 (0.95 to 1.07) | 0.82 |
BMI (kg/m²) | 0.74 (0.62 to 0.90) | 0.002 | 0.70 (0.57 to 0.87) | 0.001 | 1.18 (1.02 to 1.36) | 0.03 | 1.20 (1.02 to 1.41) | 0.03 |
Fat mass (%) | 0.99 (0.92 to 1.10) | 0.80 | 1.00 (0.92 to 1.10) | 0.92 | 1.12 (1.01 to 1.25) | 0.04 | 1.21 (1.07 to 1.38) | 0.004 |
DAS28CRP | 1.34 (0.82 to 2.19) | 0.25 | 1.38 (0.85 to 2.24) | 0.19 | 1.56 (0.87 to 2.79) | 0.14 | 1.63 (0.93 to 2.85) | 0.09 |
CRP(mg/L) | 1.06 (1.02 to 1.10) | 0.008 | 1.05 (1.01 to 1.10) | 0.02 | 1.10 (1.01 to 1.11) | 0.02 | 1.06 (1.01 to 1.11) | 0.03 |
Disease duration (years) | 1.07 (1.02 to 1.12) | 0.005 | 1.08 (1.02 to 1.36) | 0.006 | 1.05 (0.98 to 1.11) | 0.17 | 1.04 (0.97 to 1.11) | 0.25 |
CG current | ||||||||
No | ref. | ref. | ref. | ref. | ||||
Yes | 5.3 (1.15 to 24.4) | 0.03 | 5.25 (2.14 to 24.18) | 0.03 | 6.6 (0.80 to 54.37) | 0.08 | 6.5 (0.78 to 53.56) | 0.08 |
bDMARDs current | ||||||||
No | ref. | ref. | ref. | ref. | ||||
Yes | 2.72 (0.82 to 9.0) | 0.10 | 2.80 (0.84 to 9.40) | 0.10 | 3.6 (0.71 to 18.1) | 0.12 | 3.87 (0.75 to 19.95) | 0.11 |
Cumulative dose prednisone equivalent (g) | 1.04 (1.02 to 1.05) | <0.0001 | 1.04 (1.02 to 1.05) | <0.0001 | 1.02 (1.00 to 1.04) | 0.04 | 1.02 (1.00 to 1.04) | 0.05 |
≥1 × sports/ week | ||||||||
No | ref. | ref. | ref. | ref. | ||||
Yes | 0.5 (0.16 to 1.54) | 0.23 | 0.51 (0.17 to 1.60) | 0.25 | 0.26 (0.06 to 1.10) | 0.07 | 0.26 (0.06 to 1.13) | 0.07 |
HAQ (score 0–3) | 2.20 (1.17 to 4.10) | 0.02 | 2.50 (1.27 to 4.86) | 0.008 | 2.31 (1.10 to 5.04) | 0.04 | 2.77 (1.17 to 6.59) | 0.02 |
ABC-scale (0–100) | 0.98 (0.96 to 1.00) | 0.11 | 0.98 (0.96 to 1.00) | 0.11 | 0.97 (0.95 to 1.00) | 0.09 | 0.98 (0.95 to 1.00) | 0.10 |
IPAQ (total METs) | 1.00 (1.00 to 1.00) | 0.26 | 1.00 (1.00 to 1.00) | 0.27 | 1.00 (1.00 to 1.00) | 0.26 | 1.00 (1.00 to 1.00) | 0.30 |
Bold values: p<0.05 significant.
*Analyses adjusted for age and sex.
ABC-scale, Activity-specific Balance Confidence Scale; bDMARDS, biological disease-modifying antirheumatic drugs; BMI, body mass index; CG, glucocorticoids current; CRP, C reactive protein; DAS28CRP, Disease Activity Score of 28 joints including C reactive protein; EWGSOP2, European Working Group on Sarcopenia in Older People; FNIH, Foundation for the National Institutes of Health; HAQ, Health Assessment Questionnaire; IPAQ, International Physical Activity Questionnaire; MET, metabolic equivalent; RA, rheumatoid arthritis.